Introduction
============

Endocytosis is critical for the ability of cells to adapt to changes in the environment. One of its primary functions is to attenuate intracellular signaling after stimulation, through the down-regulation of plasma membrane receptors. Conversely, intracellular signaling also regulates endocytosis. The endocytosis of receptors often relies on their own signaling activity or that of a close partner, such as for receptor tyrosine kinases or G protein--coupled receptors ([@bib66]). However, intracellular signaling also influences the endocytosis of transporters ([@bib48]; [@bib3]; [@bib70]), but because transporters lack intrinsic signaling activity, this regulation remains poorly understood.

The yeast *Saccharomyces cerevisiae* is a powerful model system for studying transporter endocytosis in response to nutritional changes ([@bib21]). Numerous examples of nutrient-induced down-regulation of transporters were described since the early studies on yeast genetics and physiology. In particular, amino acid and sugar transporters were shown to undergo "catabolite inactivation" ([@bib28]; [@bib19]; [@bib21]), in which transporter activity was thought to be inactivated in response to a nutritional change, but which were later revealed as the first examples of signal-induced transporter endocytosis ([@bib24]; [@bib47]; [@bib30]; [@bib43]; [@bib21]).

*S. cerevisiae* preferentially uses glucose for growth, and glucose-starved yeast cells rapidly adapt upon exposure to glucose by remodeling their enzymatic content. For instance, glucose causes the degradation of enzymes involved in the metabolism of alternate carbon sources. In addition, glucose also induces the endocytosis of various sugar transporters ([@bib29]) and of Jen1 ([@bib55]), a monocarboxylate transporter of the SLC16/MCT family ([@bib9]). The endocytosis of transporters requires their ubiquitylation by Rsp5, a ubiquitin ligase of the Nedd4 family that harbors several members in higher eukaryotes, some of which also participate in endocytosis ([@bib62]). Therefore, the number of possible Rsp5 substrate is tremendous, leading to the question of how these transporters are specifically recognized by Rsp5, and how the timeliness of the ubiquitylation reaction is ensured. Proteins of the Nedd4/Rsp5 family are known to interact, through their WW domains, with proteins harboring a PY motif (usually, a "PPxY" sequence). However, a very limited number of membrane proteins harbor this motif. Instead, it has become clear that the interaction between Rsp5 and the transporters occurs through so-called adaptor proteins that generally display at least one PY motif ([@bib59]; [@bib39]).

In particular, several yeast proteins with homologies to arrestins (arrestin-related trafficking adaptors, or ARTs, also coined "alpha-arrestins") were proposed to recruit Rsp5 to transporters in response to changes in the environment ([@bib41]; [@bib59]; [@bib51]). Yeast arrestin-related proteins display human homologues, named ARRDC (arrestin domain-containing), which also act as adaptors of Nedd4-like enzymes ([@bib16]; [@bib49]) and are evolutionary related to β-arrestins from higher eukaryotes, which participate in endocytosis and signaling ([@bib13]; [@bib1]). Although the discovery of these arrestin-related proteins has provided a molecular basis explaining how Rsp5 interacts with and ubiquitylates transporters, it does not fully explain how transporter ubiquitylation is regulated in a timely manner with respect to the presence of extracellular signals. Indeed, phosphorylation of the metal transporter Smf1 was shown to promote the recruitment of the yeast arrestin-related protein Ecm21/Art2 ([@bib52]), but although this is required for Smf1 endocytosis it did not appear to be the trigger, suggesting the involvement of an additional regulatory step. Importantly, yeast arrestin-related proteins were described to regulate endocytosis in a signal-specific rather than transporter-specific manner ([@bib41]; [@bib51]). This raised the possibility that they become activated in response to a specific signal. However, the existence of such an activation mechanism remains unknown.

In this paper, we identified the arrestin-related protein Rod1, also named Art4, as an essential component of the glucose-induced endocytosis of Jen1, the lactate transporter. We show that Rod1 is a direct target of the glucose-signaling pathway composed of the Snf1 kinase, the yeast homologue of 5'-AMP-activated kinase (AMPK), and the protein phosphatase 1 (PP1). As such, Rod1 phosphorylation status is regulated by glucose availability, which consequently modulates its activity. In particular, we show that the glucose-induced dephosphorylation of Rod1 promotes its ubiquitylation, a modification that is essential for Jen1 endocytosis. Moreover, we demonstrate that this cross talk between dephosphorylation and ubiquitylation of Rod1 is coordinated by a phospho-dependent interaction of Rod1 with yeast 14-3-3 proteins, which inhibits Rod1 ubiquitylation. Altogether, our findings establish that Rod1 is a crucial player in glucose-induced transporter endocytosis, and provide the first molecular insights into the mechanism of arrestin-related protein activation in response to intracellular signaling.

Results
=======

The arrestin-like protein Rod1 is required for the glucose-induced endocytosis of the lactate transporter Jen1
--------------------------------------------------------------------------------------------------------------

Previous work has shown that the endocytosis of a given transporter can be mediated by various signals through the involvement of different arrestin-related proteins, suggesting that they are involved in signal-specific endocytosis ([@bib41]; [@bib51]). To gain insight into how an extracellular signal regulates endocytosis, we studied the glucose-induced endocytosis of the lactate transporter, Jen1, as a model, and first aimed to identify whether a yeast arrestin-related protein is involved in this process. We measured the down-regulation of lactate transport activity, i.e., Jen1 internalization away from the plasma membrane, after glucose addition in various mutants in which the genes encoding arrestin-related proteins were disrupted. Specifically, Jen1 was not subjected to glucose-induced inactivation in *rod1Δ*, whereas mutants for other arrestin-related genes were not affected ([Fig. 1 A](#fig1){ref-type="fig"} and [Fig. S1 A](http://www.jcb.org/cgi/content/full/jcb.201109113/DC1){#supp1}). Consistent with this observation, the glucose-induced trafficking of Jen1-GFP was abnormal in the *rod1Δ* mutant, in which Jen1 was stably localized at the plasma membrane ([Fig. 1 B](#fig1){ref-type="fig"}), and its degradation in response to glucose was strongly affected ([Fig. 1 C](#fig1){ref-type="fig"}). Rod1 was specifically involved in the regulation of glucose-induced endocytosis because neither the glucose-mediated repression of the invertase gene (*SUC2*) nor the glucose-induced degradation of fructose-1,6-bisphosphatase (Fbp1) were affected in the *rod1Δ* mutant (Fig. S1, B and C). Likewise, Rod1 was not required for Jen1 endocytosis in response to a glucose-unrelated signal, such as cycloheximide, which stimulates the endocytosis of several transporters ([@bib41]; [@bib51]) including Jen1 (Fig. S1 D). We conclude that Rod1 is not a general regulator of Jen1 endocytosis but rather participates in its "catabolite inactivation" by glucose.

![**The arrestin-related protein Rod1 is involved in the glucose-induced endocytosis of the lactate transporter, Jen1.** (A) WT and *rod1Δ* cells were grown in lactate medium, and ^14^C-labeled lactate transport activity was followed over time after glucose addition. A representative experiment of more than three repetitions is shown. The values represent the mean ± SEM of triplicate measurements. (B) Cells in which Jen1 is tagged with GFP at the chromosomal locus were grown in lactate medium, and Jen1-GFP subcellular localization was followed after glucose addition for the indicated times in WT and *rod1Δ* strains. Bar, 5 µm. (C) Total protein extracts from a similar experiment as in B were prepared at the indicated times after glucose addition and immunoblotted with the indicated antibodies. (D, top) A plasmid-encoded, galactose-inducible Jen1-GFP-His6 construct was expressed in *end3*Δ (control) and *end3Δ rod1Δ* cells. Total protein extracts were prepared at several time points after glucose addition and immunoblotted with anti-GFP or anti-PGK (loading control) antibodies. Arrowheads indicate ubiquitylated Jen1 species. (Bottom) Jen1-GFP-His6 was purified under denaturing conditions by Ni-based chromatography 10 min after glucose addition. The eluates were loaded twice and incubated with anti-GFP or anti-ubiquitin (P4D1) antibodies. (E) A *rod1Δ* strain expressing Jen1-GFP tagged at the chromosomal locus was transformed with an empty plasmid (Ø) or plasmid-encoded Rod1-3HA or Rod1-PYm-3HA, and the cells were imaged after 4 h of growth on lactate medium, and 30 min after the addition of glucose. Bar, 5 µm.](JCB_201109113_Fig1){#fig1}

The glucose-induced endocytosis of Jen1 involves its ubiquitylation by Rsp5 ([@bib56]), the sole Nedd4-like ubiquitin ligase of yeast, which was previously shown to interact with Rod1 ([@bib2]). To establish an eventual contribution of Rod1 in the Rsp5-mediated ubiquitylation of Jen1, we assessed Jen1 ubiquitylation in response to glucose in a strain devoid of Rod1. We used an endocytic mutant, *end3Δ*, which is known to accumulate transporters in a ubiquitylated state, to improve the detection of ubiquitylated conjugates. As shown in [Fig. 1 D](#fig1){ref-type="fig"}, the glucose-induced ubiquitylation of Jen1 occurred several minutes after glucose addition in the *end3*Δ strain, whereas it was strongly diminished and delayed when the *ROD1* gene was further deleted ([Fig. 1 D](#fig1){ref-type="fig"}). These results demonstrate that Rod1 is required for the rapid and efficient ubiquitylation of Jen1 in response to glucose, which may explain the endocytosis defects observed in the *rod1Δ* mutant.

The WW domains of Rsp5 interact with (L/P)PxY sequences (named "PY" motifs; [@bib62]). Rod1, like most arrestin-related proteins, displays two such PY motifs, and a point mutation in both PPxY sequences resulting in PPxA (Rod1-PYm) abolished the interaction with Rsp5 WW domains in vitro (Fig. S1 E). Although the Rod1-PYm construct was expressed at similar levels to the wild-type (WT) protein (Fig. S1 E), the mutant protein was unable to restore Jen1 endocytosis in a *rod1Δ* mutant background, suggesting an essential function for the Rod1/Rsp5 interaction in this process ([Fig. 1 E](#fig1){ref-type="fig"}). This is consistent with the role of arrestin-related proteins in assisting transporter ubiquitylation by Rsp5 ([@bib41]; [@bib52]; [@bib22]). However, because we have not observed a direct interaction between Rod1 and Jen1, we cannot exclude the possibility that Rod1 acts more indirectly on Jen1 ubiquitylation.

Rod1 phosphorylation and ubiquitylation are dynamically regulated by glucose availability
-----------------------------------------------------------------------------------------

Rod1 is therefore a major actor in the glucose-induced endocytosis of Jen1, consistent with its previous involvement in the glucose-induced endocytosis of the high-affinity glucose transporter Hxt6 ([@bib51]). We then sought to investigate how Rod1 function in endocytosis is specifically regulated by glucose availability. When cells were cultured overnight in glucose medium, the HA epitope-tagged Rod1 migrated primarily as a diffuse band on SDS-PAGE ([Fig. 2 A](#fig2){ref-type="fig"}, lane 1). This was due to Rod1 phosphorylation because phosphatase treatment of protein extracts led to a single band that displayed a faster migration. Rod1 phosphorylation was strongly enhanced when cells were grown in lactate medium (lane 2) but was rapidly lost upon glucose addition (lanes 3 and 4), revealing that Rod1 phosphorylation is controlled by glucose availability in the culture medium.

![**Dynamic modifications of Rod1 by phosphorylation and ubiquitylation are regulated by glucose availability.** (A) A WT strain expressing a plasmid-encoded Rod1-3HA was grown overnight in glucose medium (exponential phase), then 4 h in lactate medium, before glucose was added for the indicated times. Total protein extracts were either treated or untreated with calf intestinal phosphatase (CIP) and immunoblotted with anti-HA and anti-PGK antibodies. (B) A WT strain expressing plasmid-encoded Rod1-3HA and 6xHis-tagged ubiquitin was grown for 4 h in lactate medium before glucose was added for 10 min. 6xHis-tagged ubiquitin conjugates were purified under denaturing conditions by Ni-based chromatography. The lysates (Lys.) and eluates (El.) were immunoblotted with an anti-ubiquitin antibody, and with an anti-HA antibody to detect Rod1. (C) Strains expressing a plasmid-encoded Rod1-3HA or a variant mutated on both PPxY motifs (Rod1-PYm-3HA) were grown as in B. Total protein extracts were immunoblotted with an anti-HA antibody. A nonspecific, cross-reactive band was used as internal loading control. P/Ub refers to the molecular weight of phosphorylated or ubiquitylated Rod1, respectively. (D, top) Representation of Rod1 primary sequence. The numbers below show the amino acid boundaries of the predicted arrestin-related domains ("Arrestin_N"/PF00339 and "Arrestin_C"/PF02752) as determined by Pfam. The position of the Rod1 lysines that were mutated to raise the Rod1-KR-3HA construct (below) is displayed above the scheme. (Bottom) A strain expressing a plasmid-encoded Rod1-3HA or a mutant form in which the four lysines depicted in the scheme above are mutated to arginine (Rod1-KR-3HA) were grown as in A. Total protein extracts were immunoblotted with anti-HA and anti-PGK antibodies. P/Ub refers to the molecular weight of phosphorylated or ubiquitylated Rod1, respectively. (E) A *rod1Δ* strain in which Jen1 is tagged with GFP at the chromosomal locus was transformed with an empty plasmid (ø), or plasmids encoding Rod1-3HA or Rod1-KR-3HA, and grown for 3 h in lactate medium before glucose was added for the indicated times. Total protein extracts were immunoblotted with an anti-GFP antibody. Band intensities were quantified using ImageJ and the GFP\*/Jen1-GFP ratio is plotted over time. (F) Jen1-GFP subcellular localization was followed in the same strains as in E grown in similar conditions. Bar, 5 µm.](JCB_201109113_Fig2){#fig2}

This paper also revealed that exposure to glucose induced an additional post-translational modification on Rod1, which was insensitive to phosphatase treatment ([Fig. 2 A](#fig2){ref-type="fig"}, lanes 7 and 8). A common feature of Rsp5 adaptor proteins is their propensity to be ubiquitylated by Rsp5, as described for several yeast arrestin-related proteins ([@bib37]; [@bib41]; [@bib22]; [@bib25]) including Rod1 ([@bib2]). As shown in [Fig. 2 B](#fig2){ref-type="fig"}, Rod1 ubiquitylation was indeed most prominent during the lactate--glucose transition, and was dependent on its interaction with Rsp5, as indicated by the inability of the Rod1-PYm point mutant to be ubiquitylated ([Fig. 2 C](#fig2){ref-type="fig"}). The use of this mutant also confirmed that Rod1 ubiquitylation accounted for the observed phosphatase-insensitive modification mentioned above. Therefore, Rod1 dephosphorylation in response to glucose is concomitant with its ubiquitylation by Rsp5.

To determine whether this modification is important for Rod1 function, we aimed at identifying the lysine residue targeted for ubiquitylation. Using a lysine-less Rod1 construct, in which 48 lysines are mutated to arginine, and various chimeras ([Fig. S2](http://www.jcb.org/cgi/content/full/jcb.201109113/DC1){#supp2}), we mapped the ubiquitylated site(s) to a 33-residue region (aa 235--267) located in the predicted "Arrestin_C" domain and that contains four lysines ([Fig. 2 D](#fig2){ref-type="fig"}). This mutant protein (Rod1-KR) was expressed at similar levels to the WT protein, but was not functional as determined by its inability to complement the *rod1Δ* mutant for the glucose-induced Jen1 degradation and vacuolar targeting ([Fig. 2, E and F](#fig2){ref-type="fig"}), indicating an essential role of Rod1 ubiquitylation in its function in endocytosis.

Loss of Rod1 phosphorylation leads to its constitutive ubiquitylation and activation
------------------------------------------------------------------------------------

The sudden ubiquitylation of Rod1 in response to glucose and its importance for Jen1 endocytosis prompted us to study how this modification is regulated at the molecular level. We first set out to determine the eventual contribution of Rod1 phosphorylation in this process. Rod1 is a target of the Snf1 kinase ([@bib64]), the yeast homologue of AMPK, which is a crucial component of nutrient sensing and carbon metabolism regulation in eukaryotes ([@bib23]). We observed that in the *snf1Δ* mutant, Rod1 was indeed unphosphorylated ([Fig. 3 A](#fig3){ref-type="fig"}, lanes 5 and 6), but importantly, it was constitutively ubiquitylated regardless of the presence of glucose, as determined by the appearance of a phosphatase-insensitive band (lanes 7 and 8) whose presence depended on the interaction of Rod1 with Rsp5 (lane 9) and that were identified as Rod1-ubiquitin conjugates ([Fig. 3 A](#fig3){ref-type="fig"}, right). This suggested that the lack of Rod1 phosphorylation promotes its ubiquitylation. Because the Rod1 migration profile in the *snf1Δ* mutant mimics that observed at the lactate--glucose transition during which Rod1 is activated, we expressed Jen1-GFP in a strain devoid of Snf1 to study its endocytosis. However, in this mutant, very little lactate transport activity was measured after induction ([Fig. 3 B](#fig3){ref-type="fig"}). Although Jen1-GFP was expressed, it was rapidly degraded in this strain in the course of its synthesis ([Fig. 3 C](#fig3){ref-type="fig"}) and localized predominantly to intracellular compartments, including the vacuole, rather than the plasma membrane ([Fig. 3 D](#fig3){ref-type="fig"}). Strikingly, the additional deletion of *ROD1* in this mutant restored lactate transport activity, as well as Jen1 stabilization and plasma membrane localization ([Fig. 3, B--D](#fig3){ref-type="fig"}), showing that the defects observed in the absence of Snf1 were due to a constitutive, Rod1-dependent endocytosis, even in the absence of glucose.

![**The Snf1/PP1 glucose-signaling pathway regulates Rod1 activation and Jen1 endocytosis.** (A, left) WT and *snf1Δ* cells expressing plasmid-encoded Rod1-3HA or Rod1-PYm-3HA were grown in glucose overnight and then 4 h in lactate medium. Crude extracts were prepared, treated with phosphatase where indicated, and immunoblotted with the indicated antibodies. The asterisk indicates ubiquitylated Rod1 as determined by the absence of this band in cells expressing Rod1-PYm (lane 9). (Right) *snf1*Δ cells expressing plasmid-encoded Rod1-3HA and 6xHis-tagged ubiquitin were grown overnight in glucose-containing medium (exponential phase). 6xHis-tagged ubiquitin conjugates were purified under denaturing conditions by Ni-based chromatography. The lysates (Lys.) and eluates (El.) were immunoblotted with an anti-ubiquitin antibody, and with an anti-HA antibody to detect Rod1. (B) The *snf1Δ* mutant is unable to grow on alternate sugars such as galactose or nonfermentable carbon sources, but the additional deletion of *MIG1*, encoding a Snf1-regulated transcriptional repressor, allows growth on galactose ([@bib69]). Transport activity of ^14^C-labeled lactate was therefore assayed in the *snf1Δ mig1Δ* and *snf1*Δ *mig1Δ rod1Δ* strains transformed with a galactose-inducible Jen1-GFP-His6 construct after 2 h of growth in galactose medium. A representative experiment of three repetitions is shown. The values represent the mean ± SEM of triplicate measurements. (C) Crude extracts were prepared from the strains described in B. Crude extracts were prepared at the indicated times and immunoblotted with anti-GFP and anti-PGK antibodies. GFP\* indicates the size of a proteolytic fragment indicative of Jen1-GFP degradation in the vacuole. Band intensities were quantified using ImageJ and the Jen1-GFP/GFP\* ratio is plotted over time. (D) Jen1-GFP localization was followed in strains as in B after 2 h of induction. (E) A yeast two-hybrid screen using full-length Rod1 as the bait led to the identification of the C-terminal region of Reg1, a PP1 regulatory subunit. Rsp5 was used as a positive control. Average β-galactosidase activity values (Miller units) for each combination are presented. (F) WT and *reg1Δ* strains expressing plasmid-encoded Rod1-3HA were grown as indicated and total protein extracts were treated with phosphatase when indicated, and immunoblotted with the indicated antibodies. (G) WT and *reg1*Δ strains in which Jen1 is tagged with GFP at the chromosomal locus were grown for 4 h in lactate medium, and Jen1-GFP subcellular localization was followed at the indicated time after glucose addition by fluorescence microscopy. Bar, 5 µm. (H) The same strains as in G were grown in similar conditions. Samples were collected at the indicated times after glucose treatments and total protein extracts were immunoblotted with anti-GFP antibodies. GFP\* indicates the size of a proteolytic fragment indicative of Jen1-GFP degradation in the vacuole.](JCB_201109113_Fig3){#fig3}

Reg1, a regulatory subunit of protein phosphatase 1 (PP1), interacts with Rod1 and is required for Rod1 ubiquitylation and activation
-------------------------------------------------------------------------------------------------------------------------------------

A yeast two-hybrid screen using Rod1 as the bait led to the identification of the C-terminal half of Reg1 ([Fig. 3 E](#fig3){ref-type="fig"}), a regulatory subunit of the protein phosphatase PP1 that dephosphorylates and thus inactivates Snf1 in the presence of glucose ([@bib23]). This interaction involves the N-terminal region of Rod1 harboring the arrestin domain. To evaluate a putative role for PP1 in Rod1 regulation, we assessed the Rod1 phosphorylation status in a *reg1*Δ strain. Indeed, Rod1 was strongly phosphorylated in this strain ([Fig. 3 F](#fig3){ref-type="fig"}), even in glucose-grown cells, and the rapid dephosphorylation observed in WT cells during the lactate--glucose transition was strongly diminished (compare lane 3 with lane 6). Although we cannot exclude that PP1 regulates Rod1 phosphorylation through the regulation of Snf1 activity, the physical interaction between Rod1 and Reg1 as well as the rapid kinetics of Rod1 dephosphorylation in response to glucose strongly suggest that Rod1 is a new direct target of PP1. Importantly, Rod1 was not ubiquitylated in response to glucose in the *reg1Δ* mutant ([Fig. 3 F](#fig3){ref-type="fig"}, lane 9), further confirming that Rod1 dephosphorylation is required for its ubiquitylation. Therefore, Rod1 activation requires Reg1. Consistent with this, the glucose-induced endocytosis of Jen1 was impaired in the *reg1Δ* mutant ([Fig. 3, G and H](#fig3){ref-type="fig"}; and [Fig. S3 A](http://www.jcb.org/cgi/content/full/jcb.201109113/DC1){#supp3}), as reported previously for other sugar transporters ([@bib34]; [@bib29]; [@bib46]). Altogether, these results show that Rod1 ubiquitylation and activity are modulated by its phosphorylation status through the opposing activities of the Snf1 kinase and the PP1 phosphatase. Noteworthy, we confirmed that the Snf1/PP1 pathway was the only glucose-signaling pathway involved in the glucose-induced endocytosis of Jen1 (Fig. S3, B--G). Indeed, glucose-mediated Jen1 down-regulation was normal in cells deficient for the glucose sensors Snf3 and Rgt2 and the glucose receptor Gpr1 (Fig. S3, H and I).

A phosphorylation-dependent interaction of Rod1 with 14-3-3 proteins regulates Rod1 ubiquitylation
--------------------------------------------------------------------------------------------------

To better understand the molecular basis by which Rod1 dephosphorylation controls its ubiquitylation, we investigated the contribution of Rod1 phosphorylation on its interaction with Rsp5. However, coimmunoprecipitation experiments revealed that Rod1 interacted with Rsp5 under all growth conditions ([Fig. 4 A](#fig4){ref-type="fig"}), indicating that Rod1 phosphorylation status does not alter its ability to interact with Rsp5. An alternative explanation to the coupling between Rod1 dephosphorylation and its ubiquitylation came from the identification of Bmh1, one of the two redundant 14-3-3 proteins in yeast (with Bmh2), as a candidate in the yeast two-hybrid screen using Rod1 as a bait. 14-3-3 proteins are a family of conserved eukaryotic proteins involved in many cellular functions, including signaling pathways, and often interact with their partners in a phosphorylation-dependent manner ([@bib7]). To confirm this interaction in vivo, we first performed a GST pull-down using a GST-Bmh2 construct expressed in WT cells coexpressing Rod1-3HA. This confirmed that indeed, when cells are grown overnight in glucose medium, Rod1 was able to interact with Bmh2 ([Fig. 4 B](#fig4){ref-type="fig"}). Previous reports have shown that 14-3-3 proteins interact with Reg1 ([@bib46]; [@bib15]); however, the interaction between Rod1 and Bmh2 did not depend on the presence of Reg1 because Rod1 and Bmh2 were still able to interact in a *reg1Δ* deletion mutant ([Fig. 4 B](#fig4){ref-type="fig"}). Given that Rod1 phosphorylation depends on glucose availability, we assessed the dynamics of the interaction between Rod1 and Bmh2 in various conditions. As shown in [Fig. 4 C](#fig4){ref-type="fig"}, Rod1 strongly associated with Bmh2 when the cells were grown in lactate medium, but this interaction vanished in response to glucose, when Rod1 is dephosphorylated. Similarly, in the *snf1*Δ mutant, Rod1 failed to interact with Bmh2 ([Fig. 4 D](#fig4){ref-type="fig"}). This confirms that the Snf1-dependent phosphorylation of Rod1 tunes its interaction with the 14-3-3 proteins.

![**Rod1 ubiquitylation is regulated by a phospho-dependent binding to 14-3-3 proteins.** (A) WT cells expressing a plasmid-encoded Rod1-GFP construct were transformed with an empty plasmid or a plasmid encoding 3HA-Rps5. Immunoprecipitation of 3HA-Rsp5 was performed from cells grown as indicated. The input (Lys) and immunoprecipitated (IP) fractions were immunoblotted with the indicated antibodies. (B) WT and *reg1Δ* cells expressing Rod1-3HA tagged at the chromosomal locus were transformed with a plasmid encoding GST-Bmh2 or GST alone as a control. GST pull-downs were performed from cells harvested after overnight growth in glucose medium (exponential phase). The input (Lys) and pull-down (PD) fractions were immunoblotted with the indicated antibodies. Asterisk indicates a nonspecific band that sometimes cross-reacted with the anti-GST antibody. (C) WT cells in which Rod1 is tagged with GFP at the chromosomal locus were transformed with a plasmid encoding GST-Bmh2 or GST alone. GST pull-downs were performed from cells grown as indicated, and the input (Lys) and pull-down (PD) fractions were immunoblotted with the indicated antibodies. (D) WT or *snf1Δ* strains in which Rod1 is tagged with GFP at the chromosomal locus were transformed with a plasmid encoding GST-Bmh2 or GST alone and grown overnight (exponential phase) in glucose medium. GST pull-downs were performed, and input (Lys) and pull-down (PD) fractions were immunoblotted with the indicated antibodies. Asterisk indicates a nonspecific band that sometimes cross-reacted with the anti-GST antibody. (E) WT or *bmh1Δ bmh2Δ* strains expressing a plasmid-encoded Rod1-GFP were grown as indicated. Total protein extracts were treated with phosphatase when indicated to better visualize ubiquitylation, and immunoblotted with the indicated antibodies. (F) *bmh1Δ bmh2Δ* strains expressing a plasmid-encoded Rod1-GFP (WT or PYm) were grown as indicated and treated as in E.](JCB_201109113_Fig4){#fig4}

To determine the role of the 14-3-3 proteins on Rod1 ubiquitylation, we assessed its post-translational modifications in the *bmh1Δ bmh2Δ* double mutant ([@bib61]). In this mutant, Rod1 ubiquitylation was constitutive, regardless of the carbon source provided to the cells and of its phosphorylation status *(*[Fig. 4, E and F](#fig4){ref-type="fig"}), showing that in this mutant, these two modifications are uncoupled. These data indicate that the interaction between Rod1 and 14-3-3 coordinates Rod1 ubiquitylation in response to glucose availability.

Discussion
==========

The endocytosis of yeast transporters has been described for many years to be triggered by nutritional changes, especially in the case of carbon sources transporters ([@bib29]). Notably, the involvement of signaling pathway components in the regulation of the endocytosis of carbon sources transporters has been observed ([@bib33],[@bib34]; [@bib31]; [@bib46]), but there were no details as to how this regulation operates at the molecular level. Also, although it is known that the signal-induced ubiquitylation of transporters leads to their endocytosis ([@bib21]), the way by which this ubiquitylation promptly reacts to a change in nutrient availability remained unknown. Our results demonstrate that the yeast arrestin-related protein Rod1 relays intracellular signaling to transporter ubiquitylation and endocytosis.

Indeed, we established that Rod1 is a new direct target of both the Snf1 kinase and the PP1 phosphatase, Glc7/Reg1---both of which play an essential role in the regulation of carbon source utilization and metabolism ([@bib17]). Rod1 becomes rapidly activated in response to glucose replenishment, and acts as a downstream effector of the Snf1/PP1 pathway to mediate the catabolite inactivation of transporters for nonglucose carbon sources such as Jen1, providing a novel molecular basis for the regulation of transporter endocytosis by intracellular signaling. So far, the Snf1/PP1 signaling pathway was mostly documented for its role in transcriptional regulation in response to glucose ([@bib17]). Snf1 modulates gene expression upon glucose depletion through the activation of the transcriptional activators Cat8 and Adr1, and inactivation of the Mig1 transcriptional repressor, while PP1 inactivates Snf1 and therefore allows adaptation to glucose medium. Interestingly, *JEN1* promoter activity is itself regulated by Snf1, likely through the regulation of Mig1 and Cat8 ([@bib6]; [@bib42]). Our results thus illustrate an integrated physiological response to glucose fluctuations where the same actors coordinate transcriptional and post-translational regulations ([Fig. 5](#fig5){ref-type="fig"}).

![**Model for the regulation of transporter endocytosis by intracellular signaling through arrestin-related protein activation.** When yeast cells are grown in lactate medium, Snf1, the yeast AMPK homologue, is active and phosphorylates Rod1 to inactivate it (red arrows). Glucose addition triggers Jen1 endocytosis, which depends on Rod1 activation through its PP1-mediated dephosphorylation and subsequent Rsp5-mediated ubiquitylation, which are coordinated by 14-3-3 proteins (green arrows). The subcellular compartment at which Rod1 acts on Jen1 endocytosis may be the plasma membrane, or internal compartments (dashed lines). See the Discussion for details. Noteworthy, the Snf1/PP1 pathway also controls the transcriptional reprogramming of cells in response to glucose fluctuation, including the expression of the *JEN1* gene ([@bib42]), illustrating a robust physiological regulation in which transcriptional and post-translational events are coordinated.](JCB_201109113_Fig5){#fig5}

We also uncovered a new example for the regulation of ubiquitylation by substrate dephosphorylation. Cross talks between various post-translational modifications have been described ([@bib32]), notably for substrates of F-box--containing E3 ligases that are ubiquitylated in a phosphorylation-dependent manner. In contrast, PP1-mediated dephosphorylation of Rod1 promotes its ubiquitylation and activation in response to a nutritional change. Rod1 ubiquitylation appears essential for Jen1 endocytosis, although the precise role of this modification on Rod1 function remains to be elucidated. The ubiquitylation of another arrestin-related protein, Art1, is also essential for its function in endocytosis; however, its ubiquitylation appears constitutive in the conditions tested ([@bib41]), whereas Rod1 ubiquitylation is induced by glucose and may therefore provide an additional step for its regulation. The signal-dependent ubiquitylation of arrestin-related proteins has been described in filamentous fungi ([@bib26]; [@bib27]) and is reminiscent of β-arrestin ubiquitylation in mammalian cells in response to agonist treatment ([@bib13]); however, the precise mechanism by which this occurs is still unknown. Our findings are therefore likely to open new avenues toward understanding the regulation of the signal-induced ubiquitylation of arrestin-related proteins.

We further unraveled the involvement of 14-3-3 proteins in the coordination of this molecular switch by protecting phosphorylated Rod1 from ubiquitylation ([Fig. 5](#fig5){ref-type="fig"}). 14-3-3 proteins were reported to bind phosphorylated Nedd4-2, which inhibits its interaction with the sodium channel ENaC, and consequently impairs ENaC ubiquitylation and endocytosis ([@bib4]; [@bib71]; [@bib10]). We uncovered a new level of regulation by showing that 14-3-3 proteins can also regulate an intramolecular cross talk between phosphorylation and ubiquitylation on a ubiquitin ligase adaptor protein. Strikingly, a proteomic study identified most of the yeast arrestin-related proteins as phospho-dependent interactants of 14-3-3 proteins, suggestive of their more general involvement in the regulation of arrestin-related proteins ([@bib35]). Among them, Aly2/Art3 regulates the endocytosis of the basic amino acid transporter Dip5 ([@bib22]), and is phosphorylated by Npr1 ([@bib53]), a protein kinase controlled by nitrogen limitation known to regulate endocytosis ([@bib12]; [@bib21]). Aly2 is therefore a likely candidate that could be regulated in a similar manner as Rod1, but in response to nitrogen signaling.

An important question that should now be addressed in more detail is the subcellular localization of yeast arrestin-related proteins, and the compartment at which they perform their function. It was initially proposed that they are recruited and act at the plasma membrane, and at least a partial localization at this compartment was observed for several of them ([@bib41]; [@bib25]; [@bib53]). The fact that Rod1 is required for the glucose-induced ubiquitylation of Jen1 in an endocytic mutant (*end3Δ*; [Fig. 1 D](#fig1){ref-type="fig"}) suggests that Jen1 ubiquitylation indeed occurs at the plasma membrane. Rod1 is mainly a cytosolic protein, and although we did not observe a significant enrichment of Rod1 at the plasma membrane in response to glucose, this localization is still compatible with a transient function at this compartment (unpublished data). We also observed that a pool of Rod1 localizes to punctate structures (unpublished data). This is reminiscent of the observations concerning Ldb19/Art1, Aly1/Art6, or Aly2/Art3 that also localize to internal structures of an endosomal/trans-Golgi nature ([@bib41]; [@bib53]). This localization does not preclude a direct involvement of yeast arrestin-related proteins in the signal-induced ubiquitylation of transporters at intracellular compartments. Indeed, it has been proposed that Rsp5 ubiquitylates the reductive iron transporter (Fet3/Ftr1 complex) at the level of endosomes ([@bib68]). Hence, we cannot exclude that Rod1 acts, at least partially, at intracellular compartments ([Fig. 5](#fig5){ref-type="fig"}). Noteworthy, β-arrestins and the arrestin domain-containing protein ARRDC3 were proposed to regulate ubiquitylation of G protein--coupled receptor by Nedd4-like E3 ligases at endosomes ([@bib5]; [@bib63]; [@bib49]), and it may very well be that some yeast arrestin-related proteins act likewise toward certain cargoes.

In mammalian cells, the endocytosis of several solute carriers (SLCs) is known to be influenced by various signaling pathways. Recently, EGF treatment of HeLa cells was reported to lead to an increase in the ubiquitylation of many SLCs, such as members of the monocarboxylate transporter/SLC16 family, which belong to the same family as Jen1 ([@bib3]). Interestingly, in this paper SLC3A2 was reported to be modified by K63-linked ubiquitin chains, a type of ubiquitylation performed by several members of the Nedd4/Rsp5 ubiquitin ligase family ([@bib36]; [@bib38]; [@bib45]), suggesting a possible involvement of Nedd4 in the EGF-induced ubiquitylation of SLCs. Other SLCs, such as the dopamine transporter DAT/SLC6A3 and the cationic amino acid transporter CAT-1/SLC7A1 undergo a signal-induced, Nedd4-dependent ubiquitylation ([@bib67]; [@bib70]). However, how Nedd4 recognizes its target SLCs in response to a specific signal is unknown. Interestingly, mammalian arrestin domain--containing (ARRDC) proteins, like their yeast counterparts, interact with Nedd4-related ubiquitin ligases ([@bib73]; [@bib60]) and localize to the plasma membrane and/or along the endocytic pathway ([@bib54]; [@bib58]; [@bib60]; [@bib70]). In agreement with this, ARRDC3 was shown to mediate the ubiquitylation and down-regulation of plasma membrane receptors ([@bib16]; [@bib49]). It would be interesting to know whether this family of proteins is also responsible for the signal-induced ubiquitylation of SLCs.

Among these ARRDC proteins, TXNIP/VDUP-1, which regulates insulin sensitivity and energy balance in mice ([@bib11]), is particularly relevant to our paper because both TXNIP and Rod1 regulate glucose transport activity ([@bib57]; [@bib41]; [@bib51]). Cancer cells are known to display an enhanced glycolytic activity and impaired oxidative phosphorylation even under aerobic conditions (Warburg effect), similarly to *S. cerevisiae* when grown in the presence of glucose ([@bib14]). The high-affinity glucose transporters (GLUT1 and GLUT3) are overexpressed in several cancer cell lines, in which they are thought to allow an increase in glycolysis rate and thus promote tumor progression ([@bib44]). Inhibition of GLUT transporters has been used to impair the growth of tumor cells in vitro and in vivo ([@bib8]; [@bib72]), and so was the inhibition of lactate transporters in vivo ([@bib65]). Therefore, addressing the potential involvement of ARRDC proteins in the regulation of carbon sources transporter, and understanding the molecular basis of their activation in this context, might be critical to the strategies of metabolic therapies ([@bib50]).

Materials and methods
=====================

Yeast strains, transformation, and growth conditions
----------------------------------------------------

Strains are listed and detailed in [Table S1](http://www.jcb.org/cgi/content/full/jcb.201109113/DC1){#supp4}. They are derivatives of the ∑1278b background for the *bmh1bmh2*Δ strains, W303 for *snf1Δ mig1Δ*, *snf1Δ mig1Δ rod1Δ,* and *snf3Δ rgt2Δ gpr1Δ mth1Δ* strains, and BY4741/2 background for all other strains. Yeast two-hybrid screening was performed using the CTY10.5d and TAT7 strains. Yeast was transformed by standard lithium acetate/polyethylene glycol procedure. Cells were grown in yeast extract/peptone/glucose (YPD) rich medium, or in synthetic complete (SC) medium containing 2% (wt/vol) Glc, or 0.5% (vol/vol) Na-lactate, pH 5.0 (Sigma-Aldrich).

Cells were grown overnight in SC-Glc, harvested in early exponential phase (*A*~600~: 0.3), resuspended in SC-lactate, and grown for 4 h (*A*~600~: 0.6) before the addition of glucose (2% wt/vol, final concentration).

For galactose induction, cells were precultured in SC-Glc medium and grown overnight to early exponential phase (*A*~600~: 0.3) in SC medium containing 2% raffinose (wt/vol) and 0.02% Glc (wt/vol) to initiate growth. Galactose was then added at a final concentration of 2% (wt/vol) and cells were grown for the indicated times. Chase/endocytosis was started by adding glucose to a final concentration of 2% (wt/vol) and incubating for the indicated times. For galactose induction of Jen1 in [Fig. 3 D](#fig3){ref-type="fig"}, cells were directly transferred from an overnight glucose culture to a galactose-containing medium due to the slow growth of the *snf1Δ mig1Δ* mutant in raffinose.

Plasmid constructs
------------------

The plasmids used in this paper are described in [Table S2](http://www.jcb.org/cgi/content/full/jcb.201109113/DC1){#supp5}. The *p~ROD1~* :ROD1-GFP and the *p~ROD1~*:ROD1-3HA fusion were amplified from BY4741 genomic DNA, inserted into pCRII-ZeroBlunt (Invitrogen), and subcloned into SacI--XmaI sites in pRS416 (pSL93) and in pRS415 (pSL94), respectively. Site-directed mutageneses were performed by PCR using mutagenic oligonucleotides using pSL93 or pSL94 as templates. Mutagenized plasmids were checked by sequencing, and a region containing the mutation was systematically subcloned into the original pSL93/pSL94 using endogenous restriction sites to prevent mutations that may have occurred elsewhere on the plasmid. Mutation of the PPxY motifs in PPxA led to pSL118 and pSL119, respectively. Synthetic constructs from Eurofins-MWG/Operon (Ebersberg, Germany) were used to construct the lysine mutant plasmids (see Fig. S2). The *p~ROD1~:*ROD1-K0-Nter-3HA (pSL133) was obtained from a synthetic construct (lysines 10--367 mutated to arginine; \#1 in Fig. S2 A) after subcloning into endogenous PacI--BspEI sites in pSL94. The *p~ROD1~* :ROD1-K0-Cter-3HA (pSL104) construct was obtained from a synthetic construct (lysines 401--833 mutated to arginine; \#2 in Fig. S2 A) after subcloning into endogenous BspEI--XmaI sites in pSL93 and pSL94, respectively. The *p~ROD1~:*ROD1-K0-3HA (pSL134) was obtained by subcloning a PacI--BspEI fragment of pSL133 (C-terminal KR mutant) into PacI--BspEI sites in pSL104 (N-terminal KR mutant). The *p~ROD1~:*ROD1-K0-Nter-3HA (pSL133) was digested with NsiI--StuI and subcloned at NsiI--StuI sites in pSL94, giving rise to *p~ROD1~*:ROD1-K0-ArrN-3HA (pSL137; \#3 in Fig. S2 A). The complementary construct was generated by cloning a NsiI--StuI fragment of pSL94 into pSL133 at NsiI--StuI sites, giving *p~ROD1~:*ROD1-K0-ArrC-3HA (pSL138; \#4 in Fig. S2 A). Site-directed mutagenesis was performed on pSL138 to mutate three arginines R361, R365, and R367 back to lysines to obtain the *p~ROD1~:*ROD1-K16R-3HA (pSL140). The *p~ROD1~:*ROD1-K7R-3HA (pSL143; \#5 in Fig. S2 A) and *p~ROD1~:*ROD1-K9R-3HA (pSL146; \#6 in Fig. S2 A) constructs were obtained from a synthetic gene after subcloning at StuI--BspEI sites in pSL94. The *p~ROD1~:*ROD1-K(3--9)R-3HA (pSL148; \#7 in Fig. S2 A) was obtained by subcloning a PacI--NheI fragment from pSL143 into the PacI--NheI sites of pSL146. The *p~ROD1~:*ROD1-KR-3HA construct (pSL147; \#8 in Fig. S2 A), which contains four lysines mutated to arginine, was constructed by subcloning a PacI--NheI fragment from pSL146 into the PacI--NheI sites of pSL143. For the yeast two-hybrid, plasmids encoding LexA-Rod1 and LexA-Rod1 (394--837) were constructed by cloning the corresponding *ROD1* coding sequence in pLexA (1--202)+PL or pBTM116. Plasmids encoding GAD-Rsp5, GAD-Bmh1 and GAD-Reg1 were constructed by cloning the corresponding ORF in the polylinker of pACT2 (Takara Bio Inc.).

Total protein extracts, coimmunoprecipitations, and in vivo GST pull-downs
--------------------------------------------------------------------------

For total protein extracts, 1 ml of cells were harvested and precipitated on ice for 10 min with trichloroacetic acid (TCA; Sigma-Aldrich) to a final concentration of 10%. Cells were lysed with glass beads in a 100-µl volume for 10 min at 4°C and the pellet was resuspended in TCA-sample buffer (50 mM Tris-HCl, pH 6.8, 100 mM dithiothreitol, 2% SDS, 0.1% bromophenol blue, and 10% glycerol containing 200 mM of unbuffered Tris solution) at a concentration of 50 µl/initial OD unit, before being denatured at 37°C for 10 min.

Coimmunoprecipitations were performed using 20--30 OD units of cells as described below and in [@bib40]. Cells were resuspended in immunoprecipitation (IP) lysis buffer (0.1 M Tris HCl, pH 8, 0.2 M NaCl, 5% glycerol, 1 mM EDTA, 0.1% Triton X-100, 0.5 mM dithiothreitol, 1 mM phenylmethylsulfonyl fluoride, and EDTA-free protease inhibitor cocktail "Complete" (Roche) at a concentration of 1 OD unit/10 µl. Cells were disrupted with glass beads at 4°C for 10 min. Cell debris and unbroken cells were removed by a centrifugation of 5 min at 3,000 *g*, and the supernatant ("Input") was incubated with GammaBind-Sepharose beads previously incubated with the required antibody for 1 h at 4°C. The unbound fraction was eliminated by a 10-s centrifugation in a mini-centrifuge; beads were then washed three times for 10 min (at 4°C) with 1 ml of IP lysis buffer before elution of the immunoprecipitate with SDS sample buffer (1 µl/initial OD).

In vivo GST pull-down experiments were performed using the pGST (empty) and pGST-Bmh2 plasmids kindly provided by Dr. Pascual Sanz (Consejo Superior de Investigaciones Científicas \[CSIC\], Valencia, Spain; [@bib46]) following the same protocol as for the coimmunoprecipitations, but using GSH-Sepharose beads (GE Healthcare).

GST-WW recombinant protein purification and in vitro GST pull-downs
-------------------------------------------------------------------

GST-WW protein was expressed and purified from bacteria using a plasmid kindly provided by Dr. Catherine Dargemont (Institut Jacques Monod, Paris, France; [@bib20]) and purified in native conditions as follows. Bacteria were grown overnight, inoculated at 1/100 in fresh medium, and grown for 2 h. Cells were then treated with ethanol (10% final concentration) on ice for 10 min, and transferred back at 37°C for 30 min. After 2 h, protein expression was induced by adding 2.5 mg/ml IPTG and cells were grown overnight at 18°C. Bacteria were centrifuged and lysed by sonication in 10 ml cold PBS 1x/NaCl 250 mM, supplemented with protease inhibitors (Complete, EDTA-free mixture; Roche). After centrifugation (18,000 *g* for 20 min), the lysate was incubated with GSH-Sepharose beads for 1 h at 4°C. The beads were resuspended with wash buffer (1x PBS, 0.5 M NaCl, 0.1% Triton X-100, and 10% glycerol) and then loaded onto a glass Econo-column chromatography column (Bio-Rad Laboratories). Beads were then washed with an additional 40 ml of wash buffer and recombinant proteins were finally eluted with elution buffer (50 mM Tris, pH 8, and 10 mM glutathione). The eluate was dialyzed overnight at 4°C in a dialysis tubing (MWCO 10,000; Carl Roth Gmbh) in 1,000 volumes of dialysis buffer (1x PBS, 250 mM NaCl, and 10% glycerol) to eliminate the glutathione. Proteins were assayed for concentration and frozen at −80°C.

GST pull-down experiments were performed using 40 µg of recombinant proteins bound to 50 µl GSH-Sepharose beads. Crude extract incubations, washes, and elutions were performed as for the immunoprecipitation experiments.

His6-tagged ubiquitin protein conjugate purification
----------------------------------------------------

Cells were transformed with a plasmid expressing 6×Histidine-tagged ubiquitin under the control of the copper-inducible *CUP1* promoter, kindly provided by Dr. Catherine Dargemont. These experiments were performed using 100 OD units of cells, grown in exponential phase (A~600~ = 0.6), without addition of extra copper to avoid His6-tagged ubiquitin overexpression. In this situation, His6-ubiquitin expression level was similar to that of endogenous ubiquitin as determined by immunoblotting of crude extracts using an anti-ubiquitin antibody (clone P4D1; Santa Cruz Biotechnology, Inc.). Purification of His6-tagged ubiquitin protein conjugates was then performed as described below following a protocol adapted from [@bib74]. Cells were precipitated with TCA to a final concentration of 10% for 30 min on ice, and lysed with glass beads for 20 min at 4°C. After centrifugation, the pellet was resuspended with 1 ml of guanidium buffer (6 M GuHCl, 20 mM Tris-HCl, pH 8, 100 mM K~2~HPO~4~, 10 mM imidazole, 100 mM NaCl, and 0.1% Triton X-100) and incubated for 1 h at room temperature on a rotating platform. After centrifugation (16,000 *g* for 10 min at room temperature), the lysate was incubated for 2.5 h with nickel-nitriloacetic acid beads (Ni-NTA superflow; QIAGEN). The beads were then washed three times with guanidium buffer, three times with wash buffer 1 (20 mM Tris-HCl, pH 8.0, 100 mM K~2~HPO~4~, 20 mM imidazole, 100 mM NaCl, and 0.1% Triton X-100) and three times with wash buffer 2 (20 mM Tris-HCl, pH 8.0, 100 mM K~2~HPO~4~, 10 mM imidazole, 1 M NaCl, and 0.1% Triton X-100). His6-ubiquitin--conjugated proteins were finally eluted with 40 µl of elution buffer (50 mM Tris-HCl, pH 8.0, and 250 mM imidazole) for 10 min at room temperature.

Purification of His6-tagged Jen1-GFP
------------------------------------

The purification of Jen1-GFP-His6 was performed in denaturing conditions from *end3*Δ or *art4*Δ *end3*Δ cells transformed with pRHT373, encoding pGAL:Jen1-GFP-His, using nickel-nitriloacetic acid beads (Ni-NTA superflow; QIAGEN). Cells were first grown overnight in SD medium containing 2% raffinose and 0.02% glucose to initiate growth. Then, galactose was added to a final concentration of 2% for 2 h. Ubiquitylation was induced by addition of glucose (2% final concentration) for 10 min. Cells were harvested and resuspended on ice in 400 µl of cold lysis buffer (100 mM Tris-HCl, pH 7.4, 150 mM NaCl, 5 mM EDTA, 10 mM *N*-ethylmaleimide, 1 mM phenylmethylsulfonyl fluoride, and EDTA-free protease inhibitor cocktail "Complete" (Roche). Cells were lysed with glass beads and the lysate was centrifuged at 1,500 *g* for 5 min (at 4°C) to remove cell debris. The supernatant was further centrifuged for 30 min at 13,000 *g* (at 4°C). The pellet, enriched in plasma membrane proteins, was resuspended in 300 µl of buffer "M" (50 mM Tris, pH 7.4, 150 mM NaCl, 0.1% SDS, and 1% Triton X-100), and left on ice for 30 min to allow for membrane proteins solubilization. Then, TCA was added to a final concentration of 10% and the sample was incubated on ice for 30 min. Precipitated proteins were collected by centrifugation (13,000 *g* for 10 min). The pellet was washed briefly in 500 µl of unbuffered Tris solution (1 M) to neutralize the sample, and was resuspended with 800 µl of buffer "His" (50 mM Tris, pH 7.4, 150 mM NaCl, 1% Triton X-100, and 5 mM imidazole). The sample was then centrifuged for 10 min at 13,000 *g* to remove unsolubilized material, and the supernatant was incubated with 50 µl of prewashed Ni-NTA beads (Ni-NTA superflow; QIAGEN) for 1 h at 4°C, in rotation. After a brief centrifugation (10 s on a mini-centrifuge), the supernatant (unbound fraction) was collected and the beads were washed three times with buffer "His". Elution was performed with 100 µl of elution buffer (50 mM Tris, pH 7.4, 150 mM NaCl, 0.5% SDS, 1% Triton X-100, and 200 mM imidazole) after a 10-min incubation at 4°C. The eluate (8 µl) was loaded on SDS-PAGE gels.

Antibodies and immunoblotting
-----------------------------

We used monoclonal antibodies raised against GFP (clones 7.1 and 13.1; Roche), actin (clone C4; MP Biomedicals), HA (clone F7; Santa Cruz Biotechnology, Inc.), anti-ubiquitin antibody coupled to horseradish peroxidase (clone P4D1; Santa Cruz Biotechnology, Inc.), and polyclonal antibodies against GFP (a gift from Naima Belgareh, R.H. Tsapis laboratory), HA (Y11; Santa Cruz Biotechnology, Inc.), 3-phosphoglycerate kinase (PGK; clone 22CS; Invitrogen), GST (Z5; Santa Cruz Biotechnology, Inc.), FBPase (a gift from Dr. Carlos Gancedo, CSIC, Madrid, Spain), and Bmh2 (a gift from Dr. Sandra Lemmon, University of Miami, Coral Gables FL; [@bib18]). Images were acquired with the LAS-4000 imaging system (Fujifilm). Quantification was performed using ImageJ (National Institutes of Health) on nonsaturated blots.

Yeast two-hybrid analysis
-------------------------

The two-hybrid screen for LexA-Rod1 (from a pBTM116 derivative; Table S1)--interacting proteins was performed in strain TAT7 (Table S2) co-transformed with a library of *S. cerevisiae* cDNAs fused to GAD in vector pACT (a gift of S. Elledge, Baylor University, Waco, TX). His^+^ transformants (2 × 10^6^ clones) were selected in the presence of 5 mM 3-aminotriazole (3-AT) and subsequently screened for β-galactosidase activity using a filter assay. Two-hybrid assays were performed in strain CTY10.5d (Table S2) with pLexA (1--202)+PL and pACT2 plasmid derivatives (Table S1). β-Galactosidase was quantitatively assayed in permeabilized yeast cells grown to mid-log phase and expressed in Miller units. Values are average β-galactosidase activities for at least four transformants and standard errors were \<20%.

Fluorescence microscopy
-----------------------

Cells were mounted in medium and observed with a motorized fluorescence microscope (model BX-61; Olympus) equipped with a PlanApochromat 100x oil-immersion objective (1.40 NA; Olympus), a Spot 4.05 charge-coupled device camera, and the MetaVue acquisition software (Molecular Devices). Cells were mounted in SD medium and imaged at room temperature. GFP-tagged proteins were visualized using a GFP II filter (excitation wavelength 440--470 nm; Chroma Technology Corp.). Images were processed in ImageJ and Photoshop (Adobe) for levels.

Transport assays
----------------

Cells incubated under induction conditions were harvested by centrifugation and washed twice in ice-cold deionized water to a final concentration of ∼25--40 mg dry weight/ml. Conical centrifuge tubes containing 30 µl of 0.1 M KH~2~PO~4~ buffer at pH 5.0 and 10 µl of the yeast suspension were incubated for 2 min at 25°C. The reaction was started by the addition of 10 µl of an aqueous solution of 4,000 d.p.m./nmol of radiolabeled [l]{.smallcaps}-\[^14^C\]lactic acid (sodium salt; GE Healthcare) at pH 5.0. The reaction was stopped by dilution with 5 ml of ice-cold water. The reaction mixtures were filtered immediately through GF/C membranes (GE Healthcare) and the filters were washed with 10 ml of ice-cold water and transferred to scintillation fluid (Opti-Phase HiSafe II; Pharmacia LKB). Radioactivity was measured in a liquid scintillation spectrophotometer (Tri-Carb 2200 CA; Packard Instrument Co.) equipped with a d.p.m. correction facility. For nonspecific adsorption of ^14^C, labeled lactic acid was added at time zero after the cold water. All the experiments were repeated at least three times, and the data reported represent the average values. Representative experiments of at least three repetitions are presented. The data obtained are represented as the mean ± SEM of triplicate measurements.

Other methods
-------------

Dephosphorylation of yeast protein extracts was performed on protein extracts prepared as described above, and proteins were resuspended in SDS sample buffer. Samples were diluted 1:10 with phosphatase buffer and incubated for 2 h at 37°C with or without calf intestinal alkaline phosphatase, as recommended by the supplier (Roche). Proteins were then precipitated again with 10% trichloroacetic acid, resuspended in sample buffer, and analyzed by immunoblotting.

The invertase assay was performed as in [@bib69]. In brief, glucose-repressed and -derepressed cells were prepared from exponentially growing cultures in high glucose (2%) or after shifting to low glucose (0.05%) for 2.5 h. Secreted invertase was quantitatively assayed by using whole cells washed twice with cold sodium azide at 10 mM. Samples (5--50 µl) were incubated with 200 µl 0.1 M sodium acetate, pH 5.1, for 20 min at 37°C after the addition of 20 µL of 40% sucrose. Glucose standards (2.5--15 µg) were used for calibration. The reaction was stopped by boiling the tubes after addition of 200 µl of potassium phosphate (200 mM, pH 7.0). 1.0 mL glucose oxidase reagent was added, and the tubes were incubated at 37°C for 30 min. The absorbance was measured at 540 nm after addition of 1 mL of HCl 6N. Activity is expressed as micromoles of glucose released per minute per 100 mg (dry weight) of cells.

Online supplemental material
----------------------------

Tables S1 and S2 list yeast strains and plasmids used in this paper, respectively. Fig. S1 describes that Rod1 is the only yeast arrestin-like protein involved in the glucose-induced inactivation of lactate transport activity, but is not a general regulator of glucose signaling. Fig. S2 shows the mapping strategy to identify Rod1 lysines that are targets for ubiquitylation. Fig. S3 demonstrates that the Snf1/PP1 glucose-signaling pathway regulates the glucose-induced endocytosis of Jen1. Online supplemental material is available at <http://www.jcb.org/cgi/content/full/jcb.201109113/DC1>.
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